ASCO: Docetaxel Still King in Chemo-Naive mCRPC Patients (CME/CE)

(MedPage Today) -- Cabazitaxel remains a second-line therapy after docetaxel
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news